Literature DB >> 22134535

18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors.

Kevin London1, Claudia Stege, Siobhan Cross, Ella Onikul, Nicole Graf, Gertjan Kaspers, Luciano Dalla-Pozza, Robert Howman-Giles.   

Abstract

BACKGROUND: F-Fluoro-2-deoxy-D: -glucose (FDG) positron emission tomography (PET) is useful in adults with primary bone tumors. Limited published data exist in children.
OBJECTIVE: To compare hybrid FDG positron emission tomography/computed tomography (PET/CT) with conventional imaging (CI) modalities in detecting malignant lesions, predicting response to chemotherapy and diagnosing physeal involvement in pediatric primary bone tumors.
MATERIALS AND METHODS: Retrospective analysis of PET/CT and CI reports with histopathology or follow-up > 6 months as reference standard. Response parameters and physeal involvement at diagnosis were compared to histopathology.
RESULTS: A total of 314 lesions were detected in 86 scans. Excluding lung lesions, PET/CT had higher sensitivity and specificity than CI (83%, 98% and 78%, 97%, respectively). In lung lesions, PET/CT had higher specificity than CI (96% compared to 87%) but lower sensitivity (80% compared to 93%). Higher initial SUV(max) and greater SUV(max) reduction on PET/CT after chemotherapy predicted a good response. Change in tumor size on MRI did not predict response. Both PET/CT and MRI were very sensitive but of low specificity in predicting physeal tumor involvement.
CONCLUSION: PET/CT appears more accurate than CI in detecting malignant lesions in childhood primary bone tumors, excluding lung lesions. It seems better than MRI at predicting tumor response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134535     DOI: 10.1007/s00247-011-2278-x

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  26 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 2.  PET/CT in the evaluation of childhood sarcomas.

Authors:  M Beth McCarville; Ryan Christie; Najat C Daw; Sheri L Spunt; Sue C Kaste
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

3.  FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging.

Authors:  C Franzius; H E Daldrup-Link; A Wagner-Bohn; J Sciuk; W L Heindel; H Jürgens; O Schober
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

4.  Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.

Authors:  Scott M Schuetze; Brian P Rubin; Cheryl Vernon; Douglas S Hawkins; James D Bruckner; Ernest U Conrad; Janet F Eary
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

Review 5.  Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment.

Authors:  Hervé Brisse; Liliane Ollivier; Véronique Edeline; Hélène Pacquement; Jean Michon; Christophe Glorion; Sylvia Neuenschwander
Journal:  Pediatr Radiol       Date:  2004-04-22

6.  Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.

Authors:  Gi Jeong Cheon; Min Suk Kim; Jun Ah Lee; Soo-Yong Lee; Wan Hyeong Cho; Won Seok Song; Jae-Soo Koh; Ji Young Yoo; Dong Hyun Oh; Duk Seop Shin; Dae-Geun Jeon
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

Review 7.  The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.

Authors:  E Bastiaannet; H Groen; P L Jager; D C P Cobben; W T A van der Graaf; W Vaalburg; H J Hoekstra
Journal:  Cancer Treat Rev       Date:  2004-02       Impact factor: 12.111

8.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

Authors:  Thomas Völker; Timm Denecke; Ingo Steffen; Daniel Misch; Stefan Schönberger; Michail Plotkin; Juri Ruf; Christian Furth; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Holger Amthauer
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

Review 9.  Prognostic factors in osteosarcoma: a critical review.

Authors:  A M Davis; R S Bell; P J Goodwin
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

10.  18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma.

Authors:  Colleen M Costelloe; Homer A Macapinlac; John E Madewell; Nancy E Fitzgerald; Osama R Mawlawi; Eric M Rohren; A Kevin Raymond; Valerae O Lewis; Peter M Anderson; Roland L Bassett; Robyn K Harrell; Edith M Marom
Journal:  J Nucl Med       Date:  2009-03       Impact factor: 10.057

View more
  13 in total

1.  The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence.

Authors:  Andrea Angelini; Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Giulia Polverari; Giulia Trovarelli; Emanuela Palmerini; Stefano Ferrari; Stefano Fanti; Pietro Ruggieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-12       Impact factor: 9.236

2.  Pediatric nuclear medicine and pediatric radiology: modalities, image quality, dosimetry and correlative imaging: new strategies.

Authors:  Isabel Roca-Bielsa; Marina Vlajković
Journal:  Pediatr Radiol       Date:  2013-03-24

3.  Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.

Authors:  Maryam Aghighi; Justin Boe; Jarrett Rosenberg; Rie Von Eyben; Rakhee S Gawande; Philippe Petit; Tarsheen K Sethi; Jeremy Sharib; Neyssa M Marina; Steven G DuBois; Heike E Daldrup-Link
Journal:  Radiology       Date:  2016-03-16       Impact factor: 11.105

4.  Maxillary mesenchymal chondrosarcoma presenting with epistaxis in a child.

Authors:  Srinivas Anand Swaroop Uppaluri; Loi Hoi Yin; Giap Hean Goh
Journal:  J Radiol Case Rep       Date:  2015-08-31

5.  Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review.

Authors:  Sarah Kalus; Asif Saifuddin
Journal:  Eur Radiol       Date:  2019-03-26       Impact factor: 5.315

6.  How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach.

Authors:  Anne M Muehe; Ashok J Theruvath; Lillian Lai; Maryam Aghighi; Andrew Quon; Samantha J Holdsworth; Jia Wang; Sandra Luna-Fineman; Neyssa Marina; Ranjana Advani; Jarrett Rosenberg; Heike E Daldrup-Link
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

7.  A special case of lower back pain in a 3-year-old girl.

Authors:  Davide Tassinari; Sara Forti; Michele Torella; Giovanni Tani
Journal:  BMJ Case Rep       Date:  2013-03-07

8.  Diagnostic value of combined ¹⁸F-FDG PET/MRI for staging and restaging in paediatric oncology.

Authors:  Thomas Pfluger; Henriette I Melzer; Wolfgang P Mueller; Eva Coppenrath; Peter Bartenstein; Michael H Albert; Irene Schmid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

9.  The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma.

Authors:  Carmelo Caldarella; Marco Salsano; Maria Antonietta Isgrò; Giorgio Treglia
Journal:  Int J Mol Imaging       Date:  2012-09-13

10.  The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma.

Authors:  Natale Quartuccio; Giorgio Treglia; Marco Salsano; Maria Vittoria Mattoli; Barbara Muoio; Arnoldo Piccardo; Egesta Lopci; Angelina Cistaro
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.